{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T05:16:15Z","timestamp":1791609375772,"version":"4.3.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:00:00Z","timestamp":1700438400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004348","name":"Stockholm County Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018713","name":"CIMED","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jacc.2023.10.041","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T14:06:43Z","timestamp":1705327603000},"page":"417-426","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Risk of Death in Patients With Coronary Artery Disease Taking Nitrates and Phosphodiesterase-5 Inhibitors"],"prefix":"10.1016","volume":"83","author":[{"given":"Ylva","family":"Trolle Lagerros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Grotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Freyland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Grannas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4655-4837","authenticated-orcid":false,"given":"Daniel Peter","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2023.10.041_bib1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1161\/CIRCULATIONAHA.112.000056","article-title":"Sildenafil and diastolic dysfunction after acute myocardial infarction in patients with preserved ejection fraction: the Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction (SIDAMI) trial","volume":"127","author":"Andersen","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.10.041_bib2","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.amjhyper.2004.06.027","article-title":"Type 5 phosphodiesterase inhibition by sildenafil abrogates acute smoking-induced endothelial dysfunction","volume":"17","author":"Vlachopoulos","year":"2004","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jacc.2023.10.041_bib3","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ijcard.2014.12.072","article-title":"Acute effect of sildenafil on inflammatory markers\/mediators in patients with vasculogenic erectile dysfunction","volume":"182","author":"Vlachopoulos","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2023.10.041_bib4","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/heartjnl-2016-310746","article-title":"Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction","volume":"103","author":"Andersson","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2023.10.041_bib5","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.jacc.2021.01.045","article-title":"Association of phosphodiesterase-5 inhibitors versus alprostadil with survival in men with coronary artery disease","volume":"77","author":"Andersson","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.10.041_bib6","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/1074248418771896","article-title":"A\u00a0new perspective on the nitrate-phosphodiesterase type 5 inhibitor interaction","volume":"23","author":"Kloner","year":"2018","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.jacc.2023.10.041_bib7","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1161\/CIRCULATIONAHA.110.944603","article-title":"Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension","volume":"122","author":"Schwartz","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.10.041_bib8","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/bju.14813","article-title":"The global prevalence of erectile dysfunction: a review","volume":"124","author":"Kessler","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.jacc.2023.10.041_bib9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41569-021-00593-6","article-title":"Interactions between erectile dysfunction, cardiovascular disease and cardiovascular drugs","volume":"19","author":"Terentes-Printzios","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2023.10.041_bib10","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/CIR.0b013e3182447787","article-title":"Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association","volume":"125","author":"Levine","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.10.041_bib11","doi-asserted-by":"crossref","first-page":"774","DOI":"10.7326\/M21-3445","article-title":"Adverse events associated with coprescription of phosphodiesterase type 5 inhibitors and oral organic nitrates in male patients with ischemic heart disease: a case-crossover study","volume":"175","author":"Holt","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2023.10.041_bib12","first-page":"1511","article-title":"Cardiovascular outcome risks in patients with erectile dysfunction co-prescribed a phosphodiesterase type 5 inhibitor (PDE5i) and a nitrate: a retrospective observational study using electronic health record data in the United States","volume":"18","author":"Nunes","year":"2021","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.jacc.2023.10.041_bib13","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jacc.2023.10.041_bib14","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/pds.1294","article-title":"The new Swedish Prescribed Drug Register\u2014opportunities for pharmacoepidemiological research and experience from the first six months","volume":"16","author":"Wettermark","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jacc.2023.10.041_bib15","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1161\/CIRCULATIONAHA.117.029289","article-title":"Standardized endpoint definitions for coronary intervention trials: the Academic Research Consortium-2 consensus document","volume":"137","author":"Garcia-Garcia","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.10.041_bib16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/CRD.0b013e3181fb7eb8","article-title":"Erectile dysfunction: a disease marker for cardiovascular disease","volume":"19","author":"Shin","year":"2011","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.jacc.2023.10.041_bib17","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1001\/jama.294.23.2996","article-title":"Erectile dysfunction and subsequent cardiovascular disease","volume":"294","author":"Thompson","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2023.10.041_bib18","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/sj.ijir.3901604","article-title":"Erectile dysfunction prospectively associated with cardiovascular disease in the Dutch general population: results from the Krimpen Study","volume":"20","author":"Schouten","year":"2008","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.jacc.2023.10.041_bib19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1161\/CIRCOUTCOMES.112.966903","article-title":"Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies","volume":"6","author":"Vlachopoulos","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2023.10.041_bib20","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1177\/2047487317718082","article-title":"Relationship between treatment of erectile dysfunction and future risk of cardiovascular disease: a nationwide cohort study","volume":"24","author":"Vestergaard","year":"2017","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacc.2023.10.041_bib21","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1056\/NEJM200006013422201","article-title":"Hemodynamic effects of sildenafil in men with severe coronary artery disease","volume":"342","author":"Herrmann","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.10.041_bib22","doi-asserted-by":"crossref","first-page":"21C","DOI":"10.1016\/S0002-9149(99)00044-2","article-title":"Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist","volume":"83","author":"Webb","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2023.10.041_bib23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0735-1097(00)00705-1","article-title":"Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina","volume":"36","author":"Webb","year":"2000","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.10.041_bib24","article-title":"Hemodynamic effect of avanafil and glyceryl trinitrate coadministration","volume":"2013","author":"Swearingen","year":"2013","journal-title":"Drugs Context"},{"key":"10.1016\/j.jacc.2023.10.041_bib25","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.jacc.2003.09.023","article-title":"Time course of the interaction between tadalafil and nitrates","volume":"42","author":"Kloner","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.10.041_bib26","first-page":"254","article-title":"Physiology of erectile function","volume":"1","author":"Saenz de Tejada","year":"2004","journal-title":"J\u00a0Sex Med"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109723080749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109723080749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T14:00:59Z","timestamp":1760018459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109723080749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0735109723080749"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2023.10.041","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of Death in Patients With Coronary Artery Disease Taking Nitrates and Phosphodiesterase-5 Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2023.10.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}